Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nuvation Bio Inc.NYSE: NUVB
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income dips below year-ago levels
Q2 FY2026 net income of $5.4M (cash outflow) fell 90.9% year over year, behind the +155.3% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at +25.2% a year.
Context
- Net income amounted to 325.3% of revenue in FY2025, down 6888.4 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$133.97M (-34.5%) for the fiscal year ending Dec 2026, a step up from the -64.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$5.4M-200.0% QoQ
- Last fiscal yearDec 2025
- -$204.63M-64.0% YoY
- LTMJun 2026
- $112.24M+155.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -90.9% | -22.0% | +68.9 pp |
| 1 year | -64.0% | -34.5% | +29.4 pp |
| 3-year CAGR | +25.2% | -40.0% | -65.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (204.63M) USD
- Year-over-year change
- +64.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (204.63M) | +64.0% |
| FY2024 | 2024-12-31 | (567.94M) | -649.2% |
| FY2023 | 2023-12-31 | (75.8M) | +27.3% |
| FY2022 | 2022-12-31 | (104.2M) | -20.0% |
| FY2021 | 2021-12-31 | (86.85M) | — |
Net Income vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 net income of $112.24M is the smallest of the 11 companies compared; the peer median is $249.68M.
- Its year-over-year change of +155.3% is the 3rd highest of 11, against a peer median of +49.0%.
- Net income amounts to 66.1% of revenue for NUVB, versus a peer median of 544.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.18B | +848.8% | +35.4% | — | |
| LTM Jun 2026 | $401.9M | +84.1% | +49.8% | — | |
| LTM Jun 2026 | $386.97M | +12.5% | +38.2% | 544.1% | |
| LTM Jun 2026 | $314.11M | +418.0% | — | 100.8% | |
| LTM Sep 2026 | $309.06M | +37.6% | +32.1% | 275948.2% | |
| LTM Jun 2026 | $291.03M | +62.6% | +40.1% | — | |
| LTM Mar 2026 | $290.5M | +50.7% | +55.3% | 558.2% | |
| LTM Mar 2026 | $208.87M | -4.0% | +16.2% | 1154.4% | |
| LTM Sep 2026 | $191.46M | +11.5% | — | 282.2% | |
| LTM Mar 2026 | $114.48M | +47.3% | +21.7% | 529.7% | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| Peer median (excluding NUVB) | $249.68M | +49.0% | +36.8% | 544.1% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.27M | 16.29M | 19.51M | 32.28M | 35.89M |
| Change in Working Capital | 4.79M | (3.45M) | 540K | (12.51M) | (11.98M) |
| Accounts Receivables | (1.95M) | 554K | (1.22M) | (12.59M) | (3.07M) |
| Inventory | 0 | 0 | 0 | 0 | (11.41M) |
| Accounts Payables | 1.86M | (1.79M) | 70K | (1.65M) | 3.13M |
| Other Working Capital | 4.88M | (2.22M) | 1.69M | 1.74M | (630K) |
| Other Non-Cash Items | 4.41M | (4.95M) | (12.47M) | 417.08M | 5.55M |
| Operating Cash Flow | (68.19M) | (96.11M) | (68M) | (130.41M) | (173.43M) |
| Capital Expenditures | (282K) | (370K) | (69K) | (162K) | (354K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.43M | 0 |
| Purchases of Investments | (609.3M) | (520.31M) | (703.37M) | (339.65M) | (354.42M) |
| Sales of Investments | 154.91M | 584.12M | 712.35M | 450.08M | 462.29M |
| Other Investing Activities | 0 | 13K | 14K | 0 | 0 |
| Investing Cash Flow | (454.67M) | 63.46M | 8.92M | 122.7M | 99.52M |
| Debt Repayment | 0 | 0 | 0 | (4.55M) | 191.11M |
| Common Stock Issued | 0 | 0 | 0 | 4.89M | 11.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 625.53M | 1.33M | 628K | 0 | 0 |
| Financing Cash Flow | 625.53M | 1.33M | 628K | 331K | 202.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 453K | (265K) |
| Net Change in Cash | 102.67M | (31.32M) | (58.45M) | (6.93M) | 128.36M |
| Free Cash Flow | (68.47M) | (96.48M) | (68.07M) | (130.58M) | (173.78M) |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.